Stephen brings more than 20 years of global medical affairs experience. He joined Strongbridge from PTC Therapeutics where he served as vice president, medical affairs and was responsible for prelaunch planning and launch efforts for genetic neuromuscular orphan disease product development in the Americas region. Prior, Stephen led several key product launches in genetic and rare diseases, serving as executive medical director at Aegerion, senior medical director at Shire Human Genetic Therapies, European medical director at Aspreva Pharmaceuticals, and roles of increasing responsibility at GlaxoSmithKline and AstraZeneca.   Stephen brings more than 20 years of global medical affairs experience. He joined Strongbridge from PTC Therapeutics where he served as vice president, medical affairs and was responsible for prelaunch planning and launch efforts for genetic neuromuscular orphan disease product development in the Americas region. Prior, Stephen led several key product launches in genetic and rare diseases, serving as executive medical director at Aegerion, senior medical director at Shire Human Genetic Therapies, European medical director at Aspreva Pharmaceuticals, and roles of increasing responsibility at GlaxoSmithKline and AstraZeneca.

General Science